Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH 2021 | ALL and NHL patient selection for transplantation after CAR-T

Bhagirathbhai Dholaria, MBBS, of Vanderbilt University Medical Center, Nashville, TN, details how patients are selected for allogenic stem cell transplantation after chimeric antigen receptor T-cell (CAR-T) therapy. Dr Dholaria explains that patients with B-cell acute lymphoblastic leukemia (B-ALL) with certain comorbidities, recurrent measurable residual disease after CAR-T therapy, or specific molecular aberrations should be considered for allotransplantation. Additionally, patients experiencing loss of in vivo CAR-T or B-cells, or patients with hypergammaglobulinemia, are at an increased risk of relapse after CAR-T therapy. Finally, Dr Dholaria discusses how patients with prior allogenic transplantation, or those who are in remission but have previously failed CAR-T therapy, should be offered transplantation. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

Disclosures

Bhagirathbhai Dholaria, MBBS, has received research or grant support from Janssen, Takeda, MEI, Poseida, Angiocrine and Pfizer; and has received consultation/advisory board/employment fees from Jazz Pharmaceuticals.